EP3542788A1 — Topical composition comprising calcipotriol and betamethasone dipropionate
Assigned to MC2 Therapeutics Ltd · Expires 2019-09-25 · 7y expired
What this patent protects
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,wherein the polyaphron dispersion comprises calcipotriol, betamethas…
USPTO Abstract
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, andwherein the composition has a pH of 7.75 ± 0.5.
Drugs covered by this patent
- Temovate (CLOBETASOL PROPIONATE) · Fougera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.